Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
07/01/2013 | 01:27pm CEST
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at [email protected]

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
04/27 TEVA PHARMACEUTICAL INDUSTRIES : Launches AirDuo™ RespiClick® and its Auth..
04/27 TEVA PHARMACEUTICAL INDUSTRIES : embroiled in Copaxone dosage levels dispute
04/27 TEVA PHARMACEUTICAL INDUSTRIES : Patent Issued for Dose Counter and Recording Me..
04/27 TEVA PHARMACEUTICAL INDUSTRIES : Showcases CNS Portfolio at 69th Annual Meeting ..
04/27 TEVA PHARMACEUTICAL INDUSTRIES : Patent Issued for Cytokine Biomarkers as Predic..
04/27 TEVA PHARMACEUTICAL INDUSTRIES : Announces Publication of ARM-TD Study Results i..
04/26 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Vytorin® in the Uni..
04/26 TEVA PHARMACEUTICAL INDUSTRIES : Announces Planned Departure of Eyal Desheh, Gro..
04/26 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Today's Research Reports on Stocks to Wat..
04/26 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) To Restart Production At Rimsa Plan..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/26 Fresenius Shows Biotech How To Get The Deals Done
04/26 Teva mulling sale of cancer portfolio to reduce debt; shares up 1% premarket
04/25 TEVA PHARMACEUTICAL : Negative In 2015, And Still Negative In 2017
04/25 Teva finance chief to depart for likely Chairmanship at consumer credit firm
04/25 APRIL BUYS : The 14 Stocks Added To My Fund
Financials ($)
Sales 2017 23 456 M
EBIT 2017 7 071 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,80%
P/E ratio 2017 8,03
P/E ratio 2018 7,78
EV / Sales 2017 2,46x
EV / Sales 2018 2,29x
Capitalization 31 951 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results